Journal of Postgraduate Medicine
 Open access journal indexed with Index Medicus & EMBASE  
     Home | Subscribe | Feedback  

REVIEW ARTICLE
[Download PDF
 
Year : 2013  |  Volume : 59  |  Issue : 4  |  Page : 284-288  

Genetic instability in urinary bladder cancer: An evolving hallmark

N Wadhwa1, BB Mathew2, SK Jatawa1, A Tiwari1,  
1 School of Biotechnology, Rajiv Gandhi Proudyogiki Vishwavidyalaya, Bhopal, Madhya Pradesh, India
2 Department of Biotechnology, Sapthagiri College of Engineering, Bangalore, Karnataka, India

Correspondence Address:
N Wadhwa
School of Biotechnology, Rajiv Gandhi Proudyogiki Vishwavidyalaya, Bhopal, Madhya Pradesh
India

Abstract

Bladder cancer is a major health-care concern. A successful treatment of bladder cancer depends on its early diagnosis at the initial stage. Genetic instability is an essential early step toward the development of bladder cancer. This instability is found more often at the chromosomal level than at the nucleotide level. Microsatellite and chromosomal instability markers can be used as a prognostic marker for screening bladder cancer. Bladder cancer can be distinguished in two different categories according to genetic instability: Cancers with chromosomal level instability and cancers with nucleotide level instability. Deoxyribonucleic acid (DNA) mismatch repair (MMR) system and its correlation with other biologic pathway, both are essential to understand the basic mechanisms of cancer development. Microsatellite instability occurs due to defects in DNA MMR genes, including human mutL homolog 1 and human mutL homolog 2. Chromosomal alterations including deletions on chromosome 3, 8, 9, 11, 13, 17 have been detected in bladder cancer. In the current review, the most recent literature of genetic instability in urinary bladder cancer has been summarized.



How to cite this article:
Wadhwa N, Mathew B B, Jatawa S K, Tiwari A. Genetic instability in urinary bladder cancer: An evolving hallmark.J Postgrad Med 2013;59:284-288


How to cite this URL:
Wadhwa N, Mathew B B, Jatawa S K, Tiwari A. Genetic instability in urinary bladder cancer: An evolving hallmark. J Postgrad Med [serial online] 2013 [cited 2019 Nov 14 ];59:284-288
Available from: http://www.jpgmonline.com/text.asp?2013/59/4/284/123156


Full Text

 Introduction



Bladder cancer is one of the most common causes of death in India. [1] It is the fourth most common cancer in men and the eighth most common cancer in women. [2] It is seen largely in the middle and older age group. [3] It is characterized by recurrent hematuria, dysuria and increased frequency. [2] Associated risk factors include tobacco abuse, smoking, industrial carcinogens, occupational exposure and certain other non-occupational risk factors. [3],[4] Low-grade tumors (70-80%) are usually non-invasive and don't extend into the epithelial basement membrane and muscles while high grade tumors obtrude into the muscle resulting in mortality. [3] Clinical studies of transitional cell carcinoma (TCC) identify two tumor types: Superficial tumors (those that do not invade the lamina propria and are moderately differentiated) and invasive tumors (invading into and beyond the lamina propria). [5] Superficial bladder cancer is an early stage TCC, which can progress to invasive bladder cancer due to an increase in genetic instability. [1] Microsatellite instability (MSI) has been found in many cancers including bladder cancer, gall bladder cancer, ovarian cancer, colorectal cancer and has been used to detect tumor cells in bodily fluids. [6],[7],[8],[9] Continuous mutations activate oncogenes and disorganize tumor suppressor genes, which facilitates the process of oncogenesis. [10] Superficial bladder cancer at different stages and grades show distinct behavior due to genetic alteration. [1]

Genomic instability is a characteristic feature of almost all major human tumors. Numerous genetic and molecular alterations occur in TCC of the bladder. [5] Genetic instability (spontaneous and mutagen - induced) can itself lead to the development of bladder cancer. [11] It causes unscheduled mutations in deoxyribonucleic acid (DNA) repair genes and occurs at two distinct levels - chromosomal level and nucleotide level [Figure 1]. [12] Instability at the nucleotide level occurs due to faulty DNA repair systems such as base excision repair and nucleotide excision repair and results in base substitutions, deletions or insertions of a few nucleotides. [13] Microsatellites are regions of repetitive DNA sequences found ubiquitously throughout the genome. [14] MSI is caused due to defects in mismatch repair (MMR) pathway. [13] MSI can also be used as a prognostic marker for the detection of many human cancers. [15]{Figure 1}

Chromosomal instability (CIN) defines the existence of an accelerated rate of chromosomal alterations. Mutation in CIN genes results in gains or losses of whole chromosomes during cell division as well as inversions, deletions, duplications and translocations of large chromosomal segments. The effect of CIN results in aneuploidy and an increase in the rate of loss of heterozygosity (LOH). [16] LOH is the loss of a maternal or paternal allele in a tumor and are often accompanied by a gain of the opposite allele. For example - a tumor could lose the maternal chromosome 8 while duplicating the paternal chromosome 8, resulting in a normal chromosome 8 karyotype, but an abnormal chromosome 8 "allelotype" [Figure 2]. [17] CIN - related molecular markers can be used to predict progression of cancer. [15]{Figure 2}

 Defects in MMR System in Bladder Cancer



DNA MMR system plays a major role in upkeep of genomic stability. MMR removes mispaired nucleotides and insertion-deletion loops that may form during DNA replication. Insertion-deletion loops affect microsatellite sequences and involve gains or losses of short repeat units. In humans, at least six different MMR proteins are required for mismatch recognition. MutS alpha (MSH2-MSH6 heterodimer) recognizes and binds single base mispairs and insertion-deletion loops for their correction. MutS beta (MSH2-MSH3 heterodimer) also binds to insertion-deletion loops for their correction [Figure 3]. [18]{Figure 3}

Similarly, MutL alpha (MLH1-PMS2 heterodimer) coordinates the interface between the mismatch recognition complex and other MMR proteins. It also recognizes and correct insertion deletion loops. MLH1 protein may also dimerise with PMS1 (its role is still unknown) and MLH3 protein (for the correction of insertion deletion loops). MSH4 and MSH5 are additional human MMR proteins required for meiotic recombination, but have no role in MMR system. [18],[19] Loss of MMR genes lead to genetic instability in the form of chromosomal or MSI. [20],[21] Mutation of MMR genes result in the insertion or deletion of microsatellite sequences. DNA hypermethylation inactivates these genes leading to MSI. MSI is also a marker for MMR deficiency. [22]

 MSI in Bladder Cancer



Microsatellites, also known as short tandem repeats are repeating sequences of 2-6 base pairs of DNA. Microsatellite analysis is a promising marker for the detection and prognosis of bladder cancer. [2] Mutations within microsatellite sequence can be used to identify the clonal evolution of tumor cells. [6] Abnormalities in microsatellites such as MSI and LOH are commonly found in tumor cells and can be detected by polymerase chain reaction (PCR). [2] MSI occurs due to defects in MMR genes, including human mutL homolog 1 and human mutL homolog 2. Reduced expression of MMR protein is linked to MSI in bladder cancer and can be used as a new biomarker for the detection of bladder cancer. [15],[23]

Allelic loss of chromosome 9 is the most frequent event in 50-60% of bladder tumors. [14] LOH is frequently found on the chromosomal arms 4p, 8p, 9p, 11p and 17p and plays an important role in the development of bladder cancer. The reported sensitivity and specificity of this test is 85% and 90%, respectively. [24] In 80% of the cases, microsatellite analysis can indicate frequency of low-grade tumors. [2] MSI plays a significant role in evolution, initiation and progression in bladder tumors. [1] Deformity in MMR genes results in incorrect MMR causing replication errors and genetic imbalance. [1],[25] [Table 1] lists some microsatellite markers used for the detection of MSI in bladder cancer. [14],[26],[27]{Table 1}

There is a need to standardize MSI for clinical purpose as well as, new reliable methods must be developed for MSI testing, which are useful for determining MSI and its biological relationship to the disease. [28] MSI testing is an important marker for the detection of bladder cancer due to its increased sensitivity and methodological simplicity. [1]

MSI can be used to examine different samples exposed to toxic compounds and risk factors. [29] Microsatellite markers can be used to figure reoccurrence of bladder tumor in a high risk population. After validating the results at a larger scale, particular set of microsatellite markers can be used to target high risk population. [30]

 CIN in Bladder Cancer



Oxidative damage to DNA causes chromosomal aberration leading to genetic modification in cells and tissues. Bladder cancer develops due to two different genetic pathways-one forming noninvasive, papillary tumors that reoccur frequently and the other resulting in the development of carcinoma in situ, invasive high-grade cancer. [3] Such genetic instability can be assessed by using karyotyping, microsatellite analysis for PCR based techniques, comparative genomic hybridization, fluorescence in situ hybridization (FISH) or single-nucleotide polymorphism arrays. [31] Preliminary alterations in chromosome are associated with tumor ontogeny while secondary chromosomal alterations leads to its growth to a more advanced stage. [1],[25]

Chromosome 9 alterations are found in early stages of the urinary bladder cancer as LOH found in both the chromosomal arms does not depend on its stage and grade. Invasive bladder cancer is found to be associated with LOH at 11p, 3p, 13q, and 17p. [6] Genetic modification in these tumors involve deletion of 8p, 9p, 11p, 11q and Y chromosome arms and gain of 1q, 8q, 17q, and 20q chromosome arms [Table 2]. [30],[32],[33],[34],[35],[36] Mutations in p53 gene are observed in 50% of bladder cancer. The recurrence of genetic instability in invasive bladder cancer enhances the detection of urinary bladder urothelial cells in urine using FISH. [33]{Table 2}

Deletions on chromosome 3

Deletions on 3p chromosome arm have been examined in 25% cases of bladder. Deletion on this chromosome is most frequently observed at 3p12-14 in bladder cancer. At 3p14.2 region, alteration can take place during DNA replication stress, which leads to gaps or chromosome break at this site. [31] Reduced fragile histidine triad (FHIT) expression is associated with promoter hypermethylation leading to bladder cancer. [37] FHIT is a haploinsufficient tumor suppressor gene, but its role in the tumor formation is still not known. [34]

Deletions on chromosome 8

Deletion on chromosome 8 in bladder carcinoma is mostly found in its short arm (8p) which recur at the rate of 25-50% in urinary bladder cancer. [31] Deletion mapping using PCR based techniques was used to determine deletions at 8p21-22 loci. [38] Four tumor suppressor genes are reported in this region. Fasciculation and elongation protein zeta 1/leucine zipper putative tumor suppressor 1 gene located on loci 8p22 gets inactivated by transcriptional silencing in bladder cancer. The methylation status of the leucine zipper putative tumor suppressor 1 (LZTS1) promoter has not been analyzed yet. Deleted in breast cancer 2 has low mutation rate as compared to LZTS1.[31]

Deletions on chromosome 9

Chromosome 9 deletions have been found in 50% cases of bladder cancer. [6] Deactivation of tumor suppressor gene by deletion of chromosome 9 is a primary event in bladder carcinogenesis. Losses of chromosome arms are associated with progression of bladder cancer. Deletion on chromosome 9 is found at the early stages (T0 and T1) of bladder cancer while at subsequent stages, deletions on other chromosomes are also found. [31] High rate of genetic modification is found in all stages of bladder cancer. Chromosomes 9 losses like deletion of the P arm, deletion of the q arm, isochromosome 9q, monosomy of chromosome 9 are explained through molecular approaches in bladder cancer. [30] Deletion of chromosome 9 is frequently found in stage Ta grade I bladder tumors. [39] Inactivation of a reported tumor suppressor gene site on chromosome 9 is involved in the initiation of bladder cancer. [30] Five tumor suppressor genes loci have been reported on chromosome 9 which includes 9p21, 9q22.3, 9q31, 9q33, and 9q34 [Figure 4]. [31]{Figure 4}

Deletion on 9p chromosome arm affects the cyclin-dependent kinase inhibitor 2A locus, resulting in deletion or promoter hypermethylation. The detection of tumor suppressor genes on 9q chromosome arm is possible due to the fact that in many cases, LOH are found on the entire chromosome arm. [35] Deletion in 9q22.3 region results in mutation of protein patched homolog gene in bladder cancer. At 9q31 region, no tumor suppressor gene is reported till date. The tumor suppressor gene in 9q33 region is deleted in bladder cancer chromosome region candidate 1. Deletions in 9q34 region results in the mutation of the prominent tumor suppressor tuberous sclerosis complex 1 gene leading to the formation of tuberous sclerosis complex. [31]

Deletions on chromosome 11

Chromosome 11 deletions have been found in 71.43% cases of bladder cancer. Numerical changes of chromosome 11 including monosomy are commonly seen in bladder cancer. Loss of 11p chromosome arm results in the mutation of the H-RAs gene in bladder cancer. [40] Numerical aberrations on chromosome 11 results in the increase of cyclin-D copy number and its protein expression. [41] Chromosome 11 anomaly might reveal other genomic aberrations involved in the initiation and development of bladder cancer. [40]

Deletions on chromosome 13

Chromosome 13 possesses the tumor suppressor gene retinoblastoma (Rb) at 13q14 locus. LOH is reported in 30% of all the cases and its association with the advancement of tumor stages as well as its recurrence has been described. [31] p53 and Rb mutations are seen in the same neoplasm and collectively increase the frequency of tumor occurrence and shortens the survival time. [36] Rb inactivation is caused due to high and low level of Rb expression. Increase expression of Rb results in its hyperphosphorylation due to which Rb is maintained in the cytoplasm. This blocks the inhibition of the E2F transcription factors by Rb in the nucleus, thereby terminating the cell cycle. [31]

Deletions on chromosome 17

Loss of chromosome 17 has been found in 60% cases of bladder cancer. Numerical aberration on 17p chromosome arm is associated with the advancement of bladder cancer. The most important tumor suppressor gene on this chromosome is p53. [31] Mutations in p53 gene are associated with LOH at 17p13.1. Mutations in p53 gene are more commonly seen in high grade tumors than in low grade tumors. [42] Clinical trials need to be done to evaluate the effect of p53 mutation on results of therapy. Many other tumor suppressor genes are also found on chromosome 17p, but their role in bladder cancer remains unknown. [31]

 Conclusion



Successful treatment of bladder cancer depends on its early detection. MSI is becoming an important and useful marker for risk assessment and prognosis. In order to use a particular set of microsatellite markers in screening high risk populations, there is a need to validate results seen on a much larger scale. Different combinations of chromosomal lesions and expression tumor markers can be used to classify different grades and stages of bladder cancer. Interpreting the effect of CIN will affirm the basic mechanism of development and progression of bladder cancer, eventually providing hope for those afflicted. Further large scale studies on this biomarker are required to make it clinically meaningful and evidence based.

 Acknowledgment



The author would like to thank Dr. Swati Jain (Post-Doctoral Fellow, Anschutz Medical Campus Research Center, University of Colorado, Denver) for her constant encouragement throughout the study.

References

1Vaish M, Mandhani A, Mittal RD, Mittal B. Microsatellite instability as prognostic marker in bladder tumors: A clinical significance. BMC Urol 2005;5:2.
2Wadhwa N, Jatawa SK, Tiwari A. Non-invasive urine based tests for the detection of bladder cancer. J Clin Pathol 2012;65:970-5.
3Knowles MA. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis 2006;27:361-73.
4Villares da Costa AL, Wroclawski LM, Machado TM, Pompeo CA, Wroclawski ER. Non-occupational risk factors for bladder cancer. Einstein 2008;6:507-10.
5Catto JW, Meuth M, Hamdy FC. Genetic instability and transitional cell carcinoma of the bladder. BJU Int 2004;93:19-24.
6Seripa D, Parrella P, Gallucci M, Gravina C, Papa S, Fortunato P, et al. Sensitive detection of transitional cell carcinoma of the bladder by microsatellite analysis of cells exfoliated in urine. Int J Cancer 2001;95:364-9.
7Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010;138:2073-87.e3.
8Buller RE, Shahin MS, Holmes RW, Hatterman M, Kirby PA, Sood AK. p53 mutations and microsatellite instability in ovarian cancer: Yin and yang. Am J Obstet Gynecol 2001;184:891-902.
9Yoshida T, Sugai T, Habano W, Nakamura S, Uesugi N, Funato O, et al. Microsatellite instability in gallbladder carcinoma: Two independent genetic pathways of gallbladder carcinogenesis. J Gastroenterol 2000;35:768-74.
10Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
11Schabath MB, Spitz MR, Grossman HB, Zhang K, Dinney CP, Zheng PJ, et al. Genetic instability in bladder cancer assessed by the comet assay. J Natl Cancer Inst 2003;95:540-7.
12Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability: An evolving hallmark of cancer. Nat Rev Mol Cell Biol 2010;11:220-8.
13Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998;396:643-9.
14Burger M, Burger SJ, Denzinger S, Wild PJ, Wieland WF, Blaszyk H, et al. Elevated microsatellite instability at selected tetranucleotide repeats does not correlate with clinicopathologic features of bladder cancer. Eur Urol 2006;50:770-5.
15Yamamoto Y, Matsuyama H, Kawauchi S, Furuya T, Liu XP, Ikemoto K, et al. Biological characteristics in bladder cancer depend on the type of genetic instability. Clin Cancer Res 2006;12:2752-8.
16Nowak MA, Komarova NL, Sengupta A, Jallepalli PV, Shih IeM, Vogelstein B, et al. The role of chromosomal instability in tumor initiation. Proc Natl Acad Sci U S A 2002;99:16226-31.
17Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC, Nakamura Y, et al. Allelotype of colorectal carcinomas. Science 1989;244:207-11.
18Peltomäki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol 2003;21:1174-9.
19Thykjaer T, Christensen M, Clark AB, Hansen LR, Kunkel TA, Ørntoft TF. Functional analysis of the mismatch repair system in bladder cancer. Br J Cancer 2001;85:568-75.
20Vaish M. Mismatch repair deficiencies transforming stem cells into cancer stem cells and therapeutic implications. Mol Cancer 2007;6:26.
21Reese JS, Liu L, Gerson SL. Repopulating defect of mismatch repair-deficient hematopoietic stem cells. Blood 2003;102:1626-33.
22Vaish M, Mittal B. DNA mismatch repair, microsatellite instability and cancer. Indian J Exp Biol 2002;40:989-94.
23Catto JW, Xinarianos G, Burton JL, Meuth M, Hamdy FC. Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite instability. Int J Cancer 2003;105:484-90.
24Arisan S. The importance of molecular tumor markers for bladder cancer. Turk J Cancer 2003;33:171-6.
25Jones JS. Approaches to carcinoma in situ (CIS). In: Lee CT, Wood DP, editors. Bladder Cancer: Diagnosis, Therapeutics, and Management. 2 nd ed. New York, NY: Humana Press; 2010. p. 5-6.
26Berger AP, Parson W, Stenzl A, Steiner H, Bartsch G, Klocker H. Microsatellite alterations in human bladder cancer: Detection of tumor cells in urine sediment and tumor tissue. Eur Urol 2002;41:532-9.
27van Tilborg AA, Kompier LC, Lurkin I, Poort R, El Bouazzaoui S, van der Keur K, et al. Selection of microsatellite markers for bladder cancer diagnosis without the need for corresponding blood. PLoS One 2012;7:e43345.
28Lynch HT, Kaul K. Microsatellite instability, clinical implications, and new methodologies. J Natl Cancer Inst 2000;92:511-2.
29Ellegren H. Microsatellites: Simple sequences with complex evolution. Nat Rev Genet 2004;5:435-45.
30Cairns P, Shaw ME, Knowles MA. Preliminary mapping of the deleted region of chromosome 9 in bladder cancer. Cancer Res 1993;53:1230-2.
31Abraham R, Pagano F, Gomella LG, Baffa R. Chromosomal deletions in bladder cancer: Shutting down pathways. Front Biosci 2007;12:826-38.
32Sauter G, Moch H, Wagner U, Bubendorf L, Gasser TC, Mihatsch MJ. Genomic changes in urinary bladder cancer. Verh Dtsch Ges Pathol 1997;81:287-96.
33Sauter G, Simon R, Bubendorf L, Mihatsch M. Molecular genetics of urinary bladder cancer progression. Verh Dtsch Ges Pathol 2002;86:49-56.
34Mao L. Tumor suppressor genes: Does FHIT fit? J Natl Cancer Inst 1998;90:412-4.
35Kimura F, Florl AR, Seifert HH, Louhelainen J, Maas S, Knowles MA, et al. Destabilization of chromosome 9 in transitional cell carcinoma of the urinary bladder. Br J Cancer 2001;85:1887-93.
36Cote RJ, Dunn MD, Chatterjee SJ, Stein JP, Shi SR, Tran QC, et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 1998;58:1090-4.
37Iliopoulos D, Guler G, Han SY, Johnston D, Druck T, McCorkell KA, et al. Fragile genes as biomarkers: Epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene 2005;24:1625-33.
38Knowles MA, Shaw ME, Proctor AJ. Deletion mapping of chromosome 8 in cancers of the urinary bladder using restriction fragment length polymorphisms and microsatellite polymorphisms. Oncogene 1993;8:1357-64.
39Cairns P, Shaw ME, Knowles MA. Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. Oncogene 1993;8:1083-5.
40Panani AD, Babanaraki A, Malianga E, Roussos Ch. Numerical aberrations of chromosomes 9 and 11 detected by FISH in Greek bladder cancer patients. Anticancer Res 2004;24:3857-61.
41Proctor AJ, Coombs LM, Cairns JP, Knowles MA. Amplification at chromosome 11q13 in transitional cell tumours of the bladder. Oncogene 1991;6:789-95.
42Olumi AF, Tsai YC, Nichols PW, Skinner DG, Cain DR, Bender LI, et al. Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder. Cancer Res 1990;50:7081-3.

 
Thursday, November 14, 2019
 Site Map | Home | Contact Us | Feedback | Copyright  and disclaimer